-- New approval for VIMPAT® (lacosamide) CV in the U.S. as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures (PGTCS) in patients four years of age and older -- All three ...

UCB today announced new findings from analyses of pooled Vimpat(r) (lacosamide) clinical trial data, demonstrating that the new antiepileptic drug (AED) starts working during the first week of ...

ATLANTA – May 26, 2009 – press release, regulated information – UCB today announced that Vimpat® (lacosamide) C-V , a new antiepileptic drug (AED) is available in the U.S. as an add-on therapy for the ...

The FDA also approved Vimpat Injection for use in pediatric patients 4 years of age and older. The Food and Drug Administration (FDA) has approved Vimpat ® (lacosamide; UCB) as adjunctive therapy in ...

Glenmark is releasing lacosamide oral solution, 10 mg/ml, which is the generic of UCB’s Vimpat Oral Solution. Vimpat Oral Solution, 10 mg/ml had a market value of approximately $57 million for the 12 ...

New long term data showed that Vimpat® (lacosamide) C-V provided sustained reduction in seizure frequency for up to five years when used as an add-on treatment for uncontrolled partial onset seizures ...

BRUSSELS, Oct 29 (Reuters) - Shares in Belgian pharmaceutical group UCB jumped on Wednesday after U.S regulators approved its Vimpat drug as an add-on therapy for the treatment of partial-onset ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. You must not be given Vimpat® if you have ever had an allergic ...

More patients with epilepsy have a treatment option following the Food and Drug Administration's approval of an indication expansion for UCB's Vimpat (lacosamide) CV. The agency approved Vimpat as ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. Do not use if you have ever had an allergic reaction to lacosamide or ...